The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Solid Dosage Medicine Market Research Report 2024
Synopsis
Oral drug delivery is the most convenient, high patient compliant, cost effective, and safe route of administration to treat various diseases. Oral solid dosage (OSD) form refers to a final drug product that is ingested through the mouth, dissolved in the digestive system, and delivered to the body through absorption into the bloodstream. The most common OSD forms - tablets and capsules - are efficient and cost-effective to manufacture, shelf stable and easy to administer. They are widely understood and embraced by patients worldwide. They are preferred by pharmaceutical manufacturers owing to the advantage of economy of scale.
Global Oral Solid Dosage Medicine market is projected to reach US$ 502740 million in 2029, increasing from US$ 357150 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Solid Dosage Medicine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Solid Dosage Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Johnson & Johnson
Novartis
Roche
AbbVie
Merck & Co.
Bristol Myers Squibb
GlaxoSmithKline
Pfizer
Sanofi
Takeda
AstraZeneca
Bayer
Eli Lilly & Co.
Gilead Sciences
Amgen
Novo Nordisk
Teva
Boehringer Ingelheim
Biogen
Astellas
Segment by Type
Brands Drugs
Generic Drugs
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oral Solid Dosage Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Oral drug delivery is the most convenient, high patient compliant, cost effective, and safe route of administration to treat various diseases. Oral solid dosage (OSD) form refers to a final drug product that is ingested through the mouth, dissolved in the digestive system, and delivered to the body through absorption into the bloodstream. The most common OSD forms - tablets and capsules - are efficient and cost-effective to manufacture, shelf stable and easy to administer. They are widely understood and embraced by patients worldwide. They are preferred by pharmaceutical manufacturers owing to the advantage of economy of scale.
Global Oral Solid Dosage Medicine market is projected to reach US$ 502740 million in 2029, increasing from US$ 357150 million in 2022, with the CAGR of 5.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Solid Dosage Medicine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Solid Dosage Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Johnson & Johnson
Novartis
Roche
AbbVie
Merck & Co.
Bristol Myers Squibb
GlaxoSmithKline
Pfizer
Sanofi
Takeda
AstraZeneca
Bayer
Eli Lilly & Co.
Gilead Sciences
Amgen
Novo Nordisk
Teva
Boehringer Ingelheim
Biogen
Astellas
Segment by Type
Brands Drugs
Generic Drugs
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oral Solid Dosage Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Solid Dosage Medicine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Brands Drugs
1.2.3 Generic Drugs
1.3 Market by Application
1.3.1 Global Oral Solid Dosage Medicine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Solid Dosage Medicine Market Perspective (2018-2029)
2.2 Oral Solid Dosage Medicine Growth Trends by Region
2.2.1 Global Oral Solid Dosage Medicine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oral Solid Dosage Medicine Historic Market Size by Region (2018-2023)
2.2.3 Oral Solid Dosage Medicine Forecasted Market Size by Region (2024-2029)
2.3 Oral Solid Dosage Medicine Market Dynamics
2.3.1 Oral Solid Dosage Medicine Industry Trends
2.3.2 Oral Solid Dosage Medicine Market Drivers
2.3.3 Oral Solid Dosage Medicine Market Challenges
2.3.4 Oral Solid Dosage Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Solid Dosage Medicine Players by Revenue
3.1.1 Global Top Oral Solid Dosage Medicine Players by Revenue (2018-2023)
3.1.2 Global Oral Solid Dosage Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Oral Solid Dosage Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oral Solid Dosage Medicine Revenue
3.4 Global Oral Solid Dosage Medicine Market Concentration Ratio
3.4.1 Global Oral Solid Dosage Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Solid Dosage Medicine Revenue in 2022
3.5 Oral Solid Dosage Medicine Key Players Head office and Area Served
3.6 Key Players Oral Solid Dosage Medicine Product Solution and Service
3.7 Date of Enter into Oral Solid Dosage Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Solid Dosage Medicine Breakdown Data by Type
4.1 Global Oral Solid Dosage Medicine Historic Market Size by Type (2018-2023)
4.2 Global Oral Solid Dosage Medicine Forecasted Market Size by Type (2024-2029)
5 Oral Solid Dosage Medicine Breakdown Data by Application
5.1 Global Oral Solid Dosage Medicine Historic Market Size by Application (2018-2023)
5.2 Global Oral Solid Dosage Medicine Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oral Solid Dosage Medicine Market Size (2018-2029)
6.2 North America Oral Solid Dosage Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oral Solid Dosage Medicine Market Size by Country (2018-2023)
6.4 North America Oral Solid Dosage Medicine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Solid Dosage Medicine Market Size (2018-2029)
7.2 Europe Oral Solid Dosage Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oral Solid Dosage Medicine Market Size by Country (2018-2023)
7.4 Europe Oral Solid Dosage Medicine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Solid Dosage Medicine Market Size (2018-2029)
8.2 Asia-Pacific Oral Solid Dosage Medicine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oral Solid Dosage Medicine Market Size by Region (2018-2023)
8.4 Asia-Pacific Oral Solid Dosage Medicine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Solid Dosage Medicine Market Size (2018-2029)
9.2 Latin America Oral Solid Dosage Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oral Solid Dosage Medicine Market Size by Country (2018-2023)
9.4 Latin America Oral Solid Dosage Medicine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Solid Dosage Medicine Market Size (2018-2029)
10.2 Middle East & Africa Oral Solid Dosage Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oral Solid Dosage Medicine Market Size by Country (2018-2023)
10.4 Middle East & Africa Oral Solid Dosage Medicine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Oral Solid Dosage Medicine Introduction
11.1.4 Johnson & Johnson Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.1.5 Johnson & Johnson Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Oral Solid Dosage Medicine Introduction
11.2.4 Novartis Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Oral Solid Dosage Medicine Introduction
11.3.4 Roche Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.3.5 Roche Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Detail
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Oral Solid Dosage Medicine Introduction
11.4.4 AbbVie Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.4.5 AbbVie Recent Development
11.5 Merck & Co.
11.5.1 Merck & Co. Company Detail
11.5.2 Merck & Co. Business Overview
11.5.3 Merck & Co. Oral Solid Dosage Medicine Introduction
11.5.4 Merck & Co. Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.5.5 Merck & Co. Recent Development
11.6 Bristol Myers Squibb
11.6.1 Bristol Myers Squibb Company Detail
11.6.2 Bristol Myers Squibb Business Overview
11.6.3 Bristol Myers Squibb Oral Solid Dosage Medicine Introduction
11.6.4 Bristol Myers Squibb Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.6.5 Bristol Myers Squibb Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Detail
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Oral Solid Dosage Medicine Introduction
11.7.4 GlaxoSmithKline Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.7.5 GlaxoSmithKline Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oral Solid Dosage Medicine Introduction
11.8.4 Pfizer Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Oral Solid Dosage Medicine Introduction
11.9.4 Sanofi Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.9.5 Sanofi Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Oral Solid Dosage Medicine Introduction
11.10.4 Takeda Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.10.5 Takeda Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Detail
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Oral Solid Dosage Medicine Introduction
11.11.4 AstraZeneca Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.11.5 AstraZeneca Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Oral Solid Dosage Medicine Introduction
11.12.4 Bayer Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.12.5 Bayer Recent Development
11.13 Eli Lilly & Co.
11.13.1 Eli Lilly & Co. Company Detail
11.13.2 Eli Lilly & Co. Business Overview
11.13.3 Eli Lilly & Co. Oral Solid Dosage Medicine Introduction
11.13.4 Eli Lilly & Co. Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.13.5 Eli Lilly & Co. Recent Development
11.14 Gilead Sciences
11.14.1 Gilead Sciences Company Detail
11.14.2 Gilead Sciences Business Overview
11.14.3 Gilead Sciences Oral Solid Dosage Medicine Introduction
11.14.4 Gilead Sciences Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.14.5 Gilead Sciences Recent Development
11.15 Amgen
11.15.1 Amgen Company Detail
11.15.2 Amgen Business Overview
11.15.3 Amgen Oral Solid Dosage Medicine Introduction
11.15.4 Amgen Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.15.5 Amgen Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Detail
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Oral Solid Dosage Medicine Introduction
11.16.4 Novo Nordisk Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.16.5 Novo Nordisk Recent Development
11.17 Teva
11.17.1 Teva Company Detail
11.17.2 Teva Business Overview
11.17.3 Teva Oral Solid Dosage Medicine Introduction
11.17.4 Teva Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.17.5 Teva Recent Development
11.18 Boehringer Ingelheim
11.18.1 Boehringer Ingelheim Company Detail
11.18.2 Boehringer Ingelheim Business Overview
11.18.3 Boehringer Ingelheim Oral Solid Dosage Medicine Introduction
11.18.4 Boehringer Ingelheim Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.18.5 Boehringer Ingelheim Recent Development
11.19 Biogen
11.19.1 Biogen Company Detail
11.19.2 Biogen Business Overview
11.19.3 Biogen Oral Solid Dosage Medicine Introduction
11.19.4 Biogen Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.19.5 Biogen Recent Development
11.20 Astellas
11.20.1 Astellas Company Detail
11.20.2 Astellas Business Overview
11.20.3 Astellas Oral Solid Dosage Medicine Introduction
11.20.4 Astellas Revenue in Oral Solid Dosage Medicine Business (2018-2023)
11.20.5 Astellas Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
